Juvenile Idiopathic Arthritis Treatment Updates

Rheum Dis Clin North Am. 2021 Nov;47(4):545-563. doi: 10.1016/j.rdc.2021.07.009. Epub 2021 Sep 2.

Abstract

Juvenile idiopathic arthritis is a group of heterogeneous chronic inflammatory arthropathies occurring in childhood without a known cause. This article discusses the key clinical features of juvenile idiopathic arthritis and treatment updates for oligoarthritis, polyarthritis, enthesitis-related arthritis, psoriatic arthritis, and systemic arthritis. Paradigm changes in management include the earlier use of biologic agents and the introduction of biosimilars and targeted synthetic disease modifying agents like tofacitinib. This review summarizes recent developments while considering potential areas for improvement and study.

Keywords: Biologics; Biosimilars; Disease-modifying antirheumatic drugs (DMARDs); Juvenile idiopathic arthritis; Treat to target (T2T).

Publication types

  • Review

MeSH terms

  • Antirheumatic Agents* / therapeutic use
  • Arthritis, Juvenile* / drug therapy
  • Biosimilar Pharmaceuticals*
  • Humans

Substances

  • Antirheumatic Agents
  • Biosimilar Pharmaceuticals